

NeuroDex, Inc., Announces Second Award from The Michael J. Fox Foundation

NATICK, MA, USA, October 31, 2023 /EINPresswire.com/ -- <u>NeuroDex</u>, Inc. ("NeuroDex", or the "Company"), announces that it has received a second grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF), to study "Neuronal extracellular vesicles blood-based biomarker for lysosomal function."

This award will enable NeuroDex to utilize its unique <u>ExoSORT</u>™ platform□to develop an extracellular vesicle (EV) based blood biomarker for



lysosomal damage. The study will utilize an optimized procedure for neuron-derived EV (NDE) isolation to develop neuron-specific lysosomal dysfunction biomarkers.

Dr. Erez Eitan, PhD., Co-Founder and Chief Scientific Officer of NeuroDex stated, "Lysosome inhibition significantly increases EV secretion, and thus, we anticipate that EVs can be a biomarker of lysosomal function. In this study, we will test how EV-associated markers change in response to drugs that modulate autophagy and lysosome function in cell culture and human plasma."

Mr. Oded Biran, the Company's Co-Founder and CEO, stated, "We are proud to receive this additional funding from The Michael J. Fox Foundation, intended to advance the important mission of developing blood-based biomarkers for lysosomal damage." Mr. Biran added, "We believe that this grant will help NeuroDex to support clinical trials in the emerging space of lysosome base therapeutics for neurodegenerative diseases like Parkinson's."

About NeuroDex

NeuroDex is a leading developer of <u>exosome</u>-of-origin-based diagnostics, theragnostic, prognostics, and pharmacodynamics. NeuroDex's integrative research platform, called ExoSORT[™] combines bioinformatics and state-of-the-art laboratory processes. Building on all its

proprietary platform technologies (including ExoSORT[™]), NeuroDex develops a full range of exosome-of-origin, minimally invasive, blood-based diagnostics. For more information, visit <u>https://neurodex.co</u>.

Exosomes

Exosomes, also called Extracellular vesicles (EVs), are small, membrane-bound particles released by cells into the extracellular space. They play a role in intercellular communication and protein disposal and are involved in both physiological and pathological processes. Exosomes found in blood have been studied as potential diagnostic markers for a variety of diseases.

Forward-Looking Statement Disclaimer

Various statements in this release concerning NeuroDex's, future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. In addition, any forward-looking statements represent NeuroDex's views only as of the date of this release and should not be relied upon as representing their views as of any subsequent date. NeuroDex does not assume any obligation to update any forward-looking statements unless required by law.

NeuroDex Contact:

Oded Biran, CEO

info@neurodex.co

Oded Biran NeuroDex, Inc. +1 6099374811 email us here Visit us on social media: Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/665398335

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.